Mechanism, phase 3 trials, and cardiovascular outcomes — the complete record

The short version

Tirzepatide research spans from preclinical receptor assays in 2018 to large randomised trials in tens of thousands of people. The core finding is reproducible: engaging both the GIP and GLP-1 gut-hormone pathways with a single molecule produces bigger drops in blood sugar and body weight than targeting GLP-1 alone. The trial programme is unusually broad for a newer drug — seven SURPASS trials in type 2 diabetes, four SURMOUNT trials in obesity, and dedicated trials in heart failure, sleep apnea, and fatty liver disease. This page covers the mechanism, the key efficacy trials, the cardiometabolic evidence (lipid profiles, cardiovascular outcomes, heart failure), and the 2024-2025 updates.

Tirzepatide mechanism of action

Tirzepatide is the first approved dual incretin agonist, activating both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a single 39-amino-acid peptide. Engaging both receptors simultaneously enhances glucose-dependent insulin secretion (the 'incretin effect' — the amplified release of insulin that occurs in response to oral glucose), suppresses glucagon (the pancreatic hormone that raises blood sugar), slows gastric emptying, and reduces appetite and food intake. In mice and in phase 1 human studies the dual engagement produced larger glycaemic and weight effects than selective GLP-1 receptor agonism alone ^[5].

In vitro receptor-occupancy and signalling assays revealed that tirzepatide is an imbalanced dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor ^[7]. It also shows biased GLP-1 receptor signalling that favours cyclic AMP (cAMP) generation over beta-arrestin recruitment, with weaker GLP-1 receptor internalisation than native GLP-1. In primary islet experiments, beta-arrestin 1 limited the insulin response to GLP-1 but not to GIP or tirzepatide — a proposed mechanism for the enhanced insulin secretion ^[7]. The drug's fatty-acid modification produces albumin binding and an approximately 5-day elimination half-life, enabling once-weekly subcutaneous dosing ^[5].

Glycaemic efficacy: the SURPASS programme

The SURPASS programme comprises seven large phase 3 trials in adults with type 2 diabetes, using once-weekly subcutaneous doses of 5, 10, and 15 mg.

SURPASS-2 compared tirzepatide head-to-head against semaglutide 1 mg in an open-label 40-week trial in 1,879 adults. Tirzepatide 5/10/15 mg reduced HbA1c (glycated haemoglobin — the standard blood-sugar average marker) by 2.01/2.24/2.30 percentage points versus 1.86 percentage points with semaglutide — non-inferior and superior at all three doses. Reductions in body weight were also greater with tirzepatide (treatment differences -1.9, -3.6, and -5.5 kg) ^[1]. The most common adverse events were gastrointestinal and mostly mild to moderate.

SURPASS-5 enrolled adults with type 2 diabetes inadequately controlled on insulin glargine (a long-acting form of insulin). Adding once-weekly tirzepatide significantly improved glycaemic control and reduced body weight versus placebo added to the same background insulin ^[11].

SURPASS-1 substudy analysis found that at the monotherapy level, tirzepatide improved markers of beta-cell function (the pancreatic cells that produce insulin) and insulin sensitivity independently of background medications ^[12].

A pre-specified meta-analysis of all seven SURPASS RCTs (4,887 tirzepatide participants, 2,328 controls) found: MACE-4 (four-component major adverse cardiovascular event) hazard ratio 0.80 (95% CI 0.57-1.11); cardiovascular death HR 0.90 (95% CI 0.50-1.61); all-cause death HR 0.80 (95% CI 0.51-1.25). Tirzepatide did not increase MACE risk versus controls, with no effect modification across subgroups and a stronger signal in high-cardiovascular-risk participants ^[2].

Lipid outcomes: 13-RCT meta-analysis

A systematic review and meta-analysis of 14 articles from 13 randomised controlled trials examined tirzepatide's effect on the full lipid panel. Tirzepatide significantly improved all lipid markers — total cholesterol, LDL (low-density lipoprotein, the 'bad' cholesterol), HDL (high-density lipoprotein, the 'good' cholesterol), and triglycerides — with a dose-response trend across the 5, 10, and 15 mg doses. Nine of the 13 trials were rated low risk of bias ^[3].

The lipid improvement is relevant to the cardiometabolic-outcomes lens: tirzepatide's effects on atherosclerotic cardiovascular disease risk extend beyond glycaemic control to address multiple components of the metabolic syndrome (the cluster of conditions — high blood sugar, excess abdominal fat, abnormal cholesterol, high blood pressure — that increase cardiovascular risk).

Tirzepatide results across the SURMOUNT and lipid programmes are charted on the weight loss page and in the Tirzepatide references.

Beyond glucose: heart failure and cardiovascular outcomes

SUMMIT (heart failure with preserved ejection fraction) enrolled adults with HFpEF — a form of heart failure (HFpEF stands for heart failure with preserved ejection fraction, meaning the heart pumps normally but the chambers are stiff and do not fill well) and obesity. Tirzepatide reduced heart-failure events and improved patient-reported functional status ^[9].

SURPASS-CVOT — the dedicated cardiovascular outcomes trial comparing tirzepatide against an established GLP-1 receptor agonist — reported its primary endpoint in 2025 ^[10]. The full analysis adds to the SURPASS meta-analysis evidence base and directly addresses whether the MACE signal seen in the pooled programme persists versus an active cardiovascular-indication comparator.

SURMOUNT-OSA found a significant reduction in the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep, used to grade sleep apnea severity) in adults with obesity and moderate-to-severe obstructive sleep apnea, supporting the FDA approval in that indication.

Tirzepatide vs semaglutide: SURMOUNT-5 provides the most direct evidence. In 751 adults with obesity without diabetes randomised to the maximum tolerated dose of either agent, tirzepatide produced -20.2% body weight versus -13.7% with semaglutide at 72 weeks (p<0.001); tirzepatide also produced greater reductions in waist circumference and higher proportions reaching each ≥10/15/20/25% threshold ^[8].

2024-2025 updates

The most recent literature adds three important findings to the cardiometabolic evidence base.

First, the 13-RCT lipid meta-analysis ^[3] confirmed dose-responsive improvement across all four lipid markers, positioning tirzepatide as an agent that addresses the broader cardiometabolic risk profile, not only blood sugar.

Second, SUMMIT's HFpEF results ^[9] extended tirzepatide's evidence base beyond glycaemia and weight into cardiac structure and function — a clinically meaningful expansion of its cardiovascular utility.

Third, SURPASS-CVOT's 2025 primary endpoint ^[10] provides the head-to-head cardiovascular outcomes data against an established GLP-1 receptor agonist, directly addressing a gap in the pre-approval evidence base. Details are in the Tirzepatide references.

A 2025 analysis of GI tolerability alongside weight reduction further characterised the time-course of GI adverse events and their independence from the weight-loss effect ^[13].